Product Development - The lead product candidate, ML-007C-MA, is being developed for schizophrenia and Alzheimer's disease psychosis, with a target enrollment of 300 participants expected by April 2026 for the Phase 2 trial ZEPHYR, and topline results anticipated in Q3 2026[20]. - ML-007C-MA has been evaluated in four Phase 1 trials with a total of 270 healthy participants and over 1,500 doses administered, demonstrating potential for well-tolerated treatment with convenient dosing[20]. - The company is also conducting a Phase 2 trial, IRIS, for ML-004, targeting social communication deficits in autism spectrum disorder, with topline results expected in Q3 2026[26]. - ML-009, a GPR52 PAM program for hyperactivity and impulsivity, is expected to complete IND-enabling studies in 2027[27]. - ML-055, a next-generation M1/M4 muscarinic agonist, aims to advance to IND-enabling studies in 2026[27]. - The pipeline includes diverse mechanisms and neural circuits to address various CNS disorders, retaining global development and commercial rights to all programs[29]. - The company utilizes a platform combining optogenetics, single-cell transcriptomics, and STARmap to identify druggable targets within disease-related neural circuits[32]. Unmet Medical Need - Approximately 40% of the 7 million people in the U.S. living with Alzheimer's disease experience symptoms of psychosis, indicating a significant unmet need for effective treatments[22]. - Approximately 30% of patients do not respond to dopaminergic antipsychotics, and 30% to 60% have only a partial response, highlighting a significant unmet medical need[38]. - There are currently no FDA-approved therapies for Alzheimer's disease psychosis, and off-label antipsychotics carry increased mortality risks in elderly patients[40]. - The current pipeline addresses significant disease burdens, with millions affected by CNS conditions, highlighting the need for innovative therapeutic options[28]. - There are currently no FDA-approved therapies for the core symptoms of ASD, highlighting the significant need for effective treatments[129][130]. Clinical Trials and Results - The Phase 2 ZEPHYR Study for schizophrenia aims to enroll approximately 300 participants, with a primary efficacy endpoint of change in total PANSS score from baseline to week 5[114][115][117]. - The ongoing Phase 2 VISTA trial employs a 1-week titration to reach the target maintenance dose for Alzheimer's disease patients[80]. - In the ongoing Phase 2 trials, ML-007C-MA will be dosed proximal to a meal, as tolerability was improved in fed conditions compared to fasted conditions[81]. - The ongoing clinical trials for ML-007C-MA include a double-blind, placebo-controlled design, with participants randomized to receive either placebo or ML-007C-MA 210/3 mg BID[121][115]. - The ongoing Phase 2 IRIS trial has enrolled approximately 160 participants with ASD to evaluate the efficacy of ML-004, with primary endpoint results expected after 12 weeks of maintenance dosing[143]. Safety and Efficacy - The safety profile of ML-007C-MA supported advancing doses up to 210/3 mg BID and 330/6 mg QD for the Phase 2 ZEPHYR trial in schizophrenia[75]. - Most treatment-emergent adverse events (TEAEs) were mild and transient, with no serious or severe adverse events reported during the trials[77]. - At the target doses for the ongoing Phase 2 ZEPHYR trial, 67% of participants receiving 330/6 mg experienced any TEAE, compared to 25% in the placebo group[98]. - ML-007 significantly improved spatial memory in a mouse model of Alzheimer's disease, while xanomeline did not show similar effects[85]. - The predicted CSF exposures for target doses of 210/3 mg BID and 330/6 mg QD were at or above the target range for most of the dosing period[76]. Regulatory and Compliance - The FDA granted Fast Track designation to ML-007C-MA in December 2025 for treating hallucinations and delusions associated with Alzheimer's disease psychosis[20]. - The FDA review process for new drugs typically takes about 10 months from the date of filing for a standard NDA, with a total review time of approximately 12 months[187]. - The FDA may issue an approval letter or a Complete Response Letter (CRL) after evaluating a New Drug Application (NDA) and conducting inspections of manufacturing facilities[189]. - A CRL indicates that the application will not be approved in its current form and may require additional clinical data or trials[189]. - The Fast Track designation program expedites the development and review of product candidates intended to treat serious diseases and address unmet medical needs[193]. Intellectual Property and Competition - As of December 31, 2025, the company holds approximately 86 issued patents and pending patent applications related to its product candidates and proprietary technology[151]. - The patent estate includes five issued foreign patents for ML-004, with pending applications expected to expire in 2040 and 2042, depending on the application[154]. - The company relies on trademarks, trade secrets, and know-how to maintain its competitive position in neuropsychiatric medicine, with seven trademark registrations as of February 25, 2026[160]. - The biotechnology and pharmaceutical industries are characterized by intense competition, with potential competitors having greater financial resources and established market presence[166][167]. - The company is developing ML-007C-MA for the treatment of schizophrenia, facing competition from existing antipsychotic treatments and other companies developing similar products[169][170].
MapLight Therapeutics(MPLT) - 2025 Q4 - Annual Report